In a strategic move aimed at ensuring the utmost safety and efficacy, the US Food and Drug Administration (FDA) has recently announced a three-month delay in the priority review of Neurotech Pharmaceuticals' NT-501 eye cell therapy implant. This extension shifts the anticipated action date to March
The University of Texas MD Anderson Cancer Center has unveiled its ambitious new initiative, the Institute for Cell Therapy Discovery & Innovation, fueled by an impressive initial funding of over $80 million. This pioneering institute aims to revolutionize the realms of immunology and cell
Breast Cancer Awareness Month has highlighted a pressing health crisis among Indian women, particularly those aged 55 to 64. A recent report by Healthians reveals that 16% of women in this demographic are affected by breast cancer. This alarming statistic underscores the urgent need for awareness,
The pharmaceutical industry is no stranger to challenges and setbacks, especially in the area of neurological and psychiatric treatments. AbbVie, a multinational biopharmaceutical company, recently faced a significant hurdle when its promising schizophrenia drug, emraclidine, failed to meet
The recent approval of Aucatzyl by the FDA marks a significant advancement in the treatment landscape for patients with B-cell precursor acute lymphoblastic leukemia, especially those whose disease has progressed following initial chemotherapy treatments. Developed by U.K.-based Autolus
The election of Donald Trump and his return to the White House have sparked significant discussions about the potential impacts on various sectors, particularly the biopharma and vaccine industries. With anticipated shifts in federal policies and key personnel appointments, stakeholders are keenly
